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deposition studies showed the total deposited dose averaged
13% (range: 4-20%) of the inhaled dose. Of note, 5 subjects
who showed a clinical beneﬁt on study were subsequently
enrolled onto a CIS extension protocol.
Conclusion: These data are the ﬁrst to establish that CIS is
safe and can stabilize or improve lung function in HSCT re-
cipients with severe BOS, allowing systemic immunosup-
pression to be reduced. Importantly, lung deposition studies
revealed substantial delivery of CIS could be achieved in the
airways with only minimal systemic absorption.
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T Cells Mediating Acute Graft-Versus-Host Disease
Vedran Radojcic 1, Jooho Chung 2, Ann Friedman 3,
Pavan Reddy1, Bruce R. Blazar 4, Leo Luznik 5, Todd Brennan6,
Christian Siebel 7, Ivan Maillard 1,3. 1 Department of Internal
Medicine, Division of Hematology/Oncology, University of
Michigan, Ann Arbor, MI; 2 Cellular and Molecular Biology,
University of Michigan, Ann Arbor, MI; 3 Life Sciences Institute,
University of Michigan, Ann Arbor, MI; 4 Pediatric Blood and
Marrow Transplantation, University of Minnesota,
Minneapolis, MN; 5Department of Oncology, The Johns
Hopkins University School of Medicine, Baltimore, MD;
6Department of Surgery, Duke University, Durham, NC;
7 Genentech Inc., South San Francisco, CA
Blocking Notch signaling after allogeneic bone marrow
transplantation prevents acute graft-versus-host disease
(GVHD) in mice, with key roles for Notch1/2 receptors and
Delta-like-1/4 ligands (Dll1/4) (Zhang, Blood 2011; Tran, JCI
2013). To investigate the consequences of Notch inhibition in
alloantigen-speciﬁc T cells, we identiﬁed a short 2-day win-
dow of Notch activity early after transplantation during
which Notch blockade is critical for maximal prevention of
acute GVHD. We describe new mechanistic models to study
alloantigen-speciﬁc T-cells within this window, and provide
insights into early events associated with Notch blockade. In
a MHC-mismatched model, transgenic C57Bl/6 CD4+ 4C T-
cells directly recognizing host I-Ad alloantigens induced le-
thal GVHD in BALB/c recipients. 4C CD4+ T-cells were sensi-
tive to Notch blockade, which resulted in the downregulation
of Notch target genes in and impaired production of in-
ﬂammatory cytokines, concordant with ﬁndings in poly-
clonal responses (Zhang, Blood 2011; Tran, JCI 2013).
Nonetheless, serial analysis revealed preserved 4C CD4+ T-
cell activation, proliferation and expansion upon Dll1/4
blockade. In the B10.D2/BALB/c MHC-matched model of
sclerodermatous GVHD, donor-derived CD4+Vb3+ T-cells,
responding to a Mtv6-encoded BALB/c superantigen,
demonstrated massive expansion and dominant Th1 polari-
zation of Vb3+ T-cells in lymphoid tissues and the liver.
Despite this, Notch blockade in Vb3+ T-cells inhibited cyto-
kine production, but preserved activation and proliferation.
These ﬁndings document dissociated effects of Notch inhi-
bition on proliferation and cytokine production in alloan-
tigen-speciﬁc T-cells, allowing further focused evaluation of
Notch signaling functions in alloimmunity.
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Purpose: Haplo-identical transplants are increasingly used
in hematopoietic stem cell transplantation (HSCT). Do haplo-
identical transplants have a stronger graft-versus-leukemia
(GVL) effect?
Patients and Methods:We analyzed 10,679 patients with
acute leukemia undergoing HSCT from an HLA-matched
sibling donor (MSD, n¼9,815), or a haplo-identical donor
(2 HLA-antigen disparity, n¼864) between 2007e2012,
reported to the European Group for Blood and Marrow
Transplantation. In a Cox regression model, acute and
chronic GVHD were added as time-dependent variables.
Results: In the multivariate analysis, there was no differ-
ence in relapse probability between recipients of haplo-
identical or MSD grafts. This was seen in T-cell replete and
T-cell depleted grafts analyzed separately. Factors of
importance for relapse among T-cell replete grafts included
remission status at HSCT, Karnofsky score 80, acute GVHD
grade II, and chronic GVHD (p<10-5). Among patients
receiving T-cell depleted grafts, advanced disease (p<10-5)
and second remission (p¼0.01) compared to ﬁrst remission
were the strongest factors for leukemic relapse. Non-
relapse mortality was signiﬁcantly higher in the haplo
group versus MSD transplants among patients receiving T-
cell repleted grafts or T-cell depleted grafts (p<10-5).
Subsequently, leukemia-free survival was superior in the
MSD group of T-cell replete grafts (p<10-5) and T-cell
depleted grafts (p¼0.0006).
Conclusion: Risk of relapse was the same in patients with
acute leukemia in haplo-identical transplant recipients
compared with MSD transplants, suggesting a similar
GVL effect.508
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Introduction: We describe a case of a 52-year-old man with
history of refractory angioimmunoblastic T-cell lymphoma
11months aftermatched unrelated allogeneic hematopoietic
cell transplant with acute ﬁbrinous organizing pneumonitis
successfully treated with high dose steroids, tacrolimus, and
8 doses of etanercept.
Case presentation: A 52-year-old Caucasian male with a
history of refractory stage IV angioimmunoblastic T-cell
lymphoma treated with CHOP, ICE and Romidepsin fol-
lowed by ATG/TBI matched unrelated allogeneic he-
matopoietic cell transplant (HCT) in March 2013. He had
an uncomplicated course with the exception of mild
classic chronic GVHD of skin treated with topical ste-
roids. Eleven months after HCT, he was off
Figure 1. Biopsy wedge resection left upper lobe consistent with acute organizing ﬁbrinous pneumonitis (AFOP)
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our institutions protocol when he presented to clinic
with dry cough, dyspnea, and oxygen saturations in mid
60% on room air. A chest CT demonstrated signiﬁcant
multifocal nodular opacities and ground glass in all lung
ﬁelds (ﬁgure 1) as well as enlargement of axilla, sub
pectoral and mediastinal lymph nodes. He underwent a
non-diagnostic bronchoscopy followed by VATS left up-
per lobe and left lower lobe wedge resections. The pa-
thology revealed acute organizing ﬁbrinous pneumonitis
(AFOP) (ﬁgure 2). He was intubated in the intensive care
unit for 2 days after VATS wedge resection procedure.
Therapy for AFOP was initiated methylprednisolone
1000mg daily in divided doses along with tacrolimus.
Several days later etanercept 25mg SQ twice weekly was
initiated because patient was not improving his
oxygenation. He received a total of 8 doses of eta-
nercept. His recovery was complicated by prolonged
pneumothorax and pneumomediastium requiring a
pigtail catheter. He returned to the operating room for
decortication, mechanical pleurodesis and chest tube
placement. Eight days postoperatively the chest tube
was removed. He was weaned of oxygen in seven days.
Repeat chest CT demonstrated improved multifocal
airspace disease (ﬁgure 1) and he is still without oxygen
as of September 2014.
Discussion: To the best of our knowledge this is the ﬁrst
case demonstrating the successful treatment of AFOP, a
sub-type of pulmonary chronic GVHD, with etanercept.
Etanercept is an inhibitor of tumor necrosis factor-alpha
(TNF-alpha).Figure 2. CT images before509
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University Hospital, Stockholm, SwedenGraft versus host disease (GvHD) is a common and severe
complication after allogeneic stem cell transplantation.
During pregnancy, the placenta and the fetal membranes
function as an immunological barrier, protecting the fetus
from the mother’s immune system.We have isolated stromal
cells from the decidual layer of term placentas. These
decidual stromal cells (DSCs) are of maternal origin, and
strongly inhibit the alloreactivity of T-cells in vitro. The effect
is mainly contact dependent, and decreases the production
of several key cytokines involved in the cytokine storm
promoting the continuation of GvHD.
To investigate the effect of DSCs on acute GvHD we
enrolled 32 patients diagnosed with acute GvHD grade 2-4
and clinically non-responsive to standard therapy. The pro-
tocol was changed after 17 patients, the DSCs were then
thawed and infused in infusion solution with albumin
instead of AB-plasma and given repeatedly and earlier uponand after etanercept
